Middle East & Africa Respiratory Disease Vaccine Market Size & Outlook
Related Markets
MEA respiratory disease vaccine market highlights
- The MEA respiratory disease vaccine market generated a revenue of USD 3,818.2 million in 2023.
- The market is expected to grow at a CAGR of 0.9% from 2024 to 2030.
- In terms of segment, viral vaccine was the largest revenue generating type in 2023.
- Bacterial Vaccine is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 3,818.2 million |
| Market revenue in 2030 | USD 4,069.7 million |
| Growth rate | 0.9% (CAGR from 2023 to 2030) |
| Largest segment | Viral vaccine |
| Fastest growing segment | Bacterial Vaccine |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Viral Vaccine, Bacterial Vaccine, Combination Vaccine |
| Key market players worldwide | GSK PLC, Johnson & Johnson, Pfizer Inc, Sanofi SA, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd, Bavarian Nordic A/S, Merck & Co Inc, AstraZeneca PLC, Emergent BioSolutions Inc, Novavax Inc, Inovio Pharmaceuticals Inc, Moderna Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 5.9% of the global respiratory disease vaccine market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 20,261.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Respiratory Disease Vaccine Market Scope
Respiratory Disease Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novavax Inc | View profile | 1992 | 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 | https://www.novavax.com |
| Inovio Pharmaceuticals Inc | View profile | 122 | 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, United States, 19462 | https://www.inovio.com |
| Bavarian Nordic A/S | View profile | 1381 | Philip Heymans Alle 3, Hellerup, Denmark, DK-2900 | https://www.bavarian-nordic.com |
| Moderna Inc | View profile | 5600 | 200 Technology Square, Cambridge, MA, United States, 02139 | https://www.modernatx.com |
| Emergent BioSolutions Inc | View profile | 1600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | https://www.emergentbiosolutions.com |
| Sinovac Biotech Ltd | View profile | 3261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | http://www.sinovac.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | http://www.seruminstitute.com/ |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Middle East & Africa respiratory disease vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to respiratory disease vaccine market will help companies and investors design strategic landscapes.
Viral vaccine was the largest segment with a revenue share of 54.84% in 2024. Horizon Databook has segmented the Middle East & Africa respiratory disease vaccine market based on viral vaccine, bacterial vaccine, combination vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Middle East & Africa respiratory disease vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa respiratory disease vaccine market databook
-
Our clientele includes a mix of respiratory disease vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa respiratory disease vaccine market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa respiratory disease vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA respiratory disease vaccine market size, by country, 2018-2030 (US$M)
Middle East & Africa Respiratory Disease Vaccine Market Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
